We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cannabidiol Enhances Cabozantinib-Induced Apoptotic Cell Death via Phosphorylation of p53 Regulated by ER Stress in Hepatocellular Carcinoma.
- Authors
Jeon, Youngsic; Kim, Taejung; Kwon, Hyukjoon; Kim, Jeong-Kook; Park, Young-Tae; Ham, Jungyeob; Kim, Young-Joo
- Abstract
Simple Summary: This study provides evidence that cabozantinib and CBD combination treatment leads to increased apoptosis in HCC cells. We propose that this enhanced apoptosis is mediated, at least in part, through the induction of ER stress and subsequent activation of the p53 pathway. However, our study did not find any association between the combination treatment and CNR. Cannabidiol (CBD), a primary constituent in hemp and cannabis, exerts broad pharmacological effects against various diseases, including cancer. Additionally, cabozantinib, a potent multi-kinase inhibitor, has been approved for treating patients with advanced hepatocellular carcinoma (HCC). Recently, there has been an increase in research on combination therapy using cabozantinib to improve efficacy and safety when treating patients. Here, we investigated the effect of a combination treatment of cabozantinib and CBD on HCC cells. CBD treatment enhanced the sensitivity of HCC cells to cabozantinib-mediated anti-cancer activity by increasing cytotoxicity and apoptosis. Phospho-kinase array analysis demonstrated that the apoptotic effect of the combination treatment was mainly related to p53 phosphorylation regulated by endoplasmic reticulum (ER) stress when compared to other kinases. The inhibition of p53 expression and ER stress suppressed the apoptotic effect of the combination treatment, revealing no changes in the expression of Bax, Bcl-2, cleaved caspase-3, cleaved caspase-8, or cleaved caspase-9. Notably, the effect of the combination treatment was not associated with cannabinoid receptor 1 (CNR1) and the CNR2 signaling pathways. Our findings suggest that the combination therapy of cabozantinib and CBD provides therapeutic efficacy against HCC.
- Subjects
THERAPEUTIC use of antineoplastic agents; CANNABIDIOL; ENDOPLASMIC reticulum; APOPTOSIS; CELL receptors; CELLULAR signal transduction; TUMOR suppressor genes; RESEARCH funding; MOLECULAR structure; CELL surface antigens; COMBINED modality therapy; CELL death; PHOSPHORYLATION; HEPATOCELLULAR carcinoma; IMMUNODIAGNOSIS; CASPASES
- Publication
Cancers, 2023, Vol 15, Issue 15, p3987
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers15153987